Company: BGLC
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001477932-25-008343
Chunk: 3

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 3
---
 (2,303,840)  (5,851,951)  (6,006,504)                 GROSS PROFIT  377,685   326,536   1,089,200   980,287                  OTHER INCOME                Dividend income   4,192   38,826   21,752   59,653 Interest income  20,778   35,022   74,114   113,744 Fair value gain on investments in equity securities  -   69,766   28,256   243,083 Gain on disposal of investments in equity securities  42,376   20,800   42,376   35,098 Reversal of expected credit losses  -   257,986   94,912   842,401 Others  40,414   43,127   147,231   103,500 TOTAL OTHER INCOME  107,760   465,527   408,641   1,397,479                  OPERATING EXPENSES                Sales and marketing  (551,569)  (1,245,456)  (1,700,691)  (1,535,821)Research and development  (14,876)  (10,442)  (39,572)  (30,115)General and administrative (including $1,065 and $1,006 of rental expenses to related party for the three months period ended September 30, 2025 and 2024, respectively, including $3,156 and $1,006 of rental expenses to related party for the nine months period ended September 30, 2025 and 2024, respectively)  (445,691)  (792,413)  (1,354,357)  (1,667,036)Fair value loss on investments in equity securities  -   (79,000)  (119,499)  (179,433)Provision for expected credit losses   (175,818)  (2,374)  (215,942)  (122,843)TOTAL OPERATING EXPENSES  (1,187,954)